Kivu Bioscience
At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
$92M Series A ·
Led by Novo Holdings · Source: fundraisingfox.com
Funding history ↓Signals
Website registeredJun 22, 2023 (3 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $92M | fundraisingfox.com |
Timeline
- Website created
Team
AM
Ann MacLaren SVP and Head of Translational MedicineBS
Brunilda Shtylla Chief Business OfficerLZ
Liangyi Zhang VP & Head of CMCMT
Mohit Trikha President & COOSR
Sophia Randolph Chief Medical Officer
Investors
BBioGeneration Ventures
BBOM
GGimv
HHealthCap
MM Ventures
NNovo Holdingslead investor
RRed Tree Venture Capital
Companies like Kivu Bioscience
HHaptena Therapeutics$3.53M Seed · Dec 2025FFoRx Therapeutics$50M Series A · Dec 2025
RReprogram Biosciences$6M Seed · May 2026
EElement Biosciences$175M Series B+ · Jun 2026
CCrossbow Therapeutics$77M Series B+ · Mar 2026
PPahtiā TechnologiesSeed · Sep 2026
Other companies backed by Novo Holdings
OOMass Therapeutics$310M Series B+ · Oct 2026
AAnaCardio$70.97M Series B+ · Sep 2026
BBreye Therapeutics$76.65M Series A · Sep 2026
CClaris Bio$118M Series B+ · Jul 2026
BBactolife$34.9M Series B+ · Jan 2026
SSidera Bio$109.99M Series A · Nov 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/kivu-bioscience (get a free API key).